Skip to main content
Premium Trial:

Request an Annual Quote

Italy Signs on to Participate in ELIXIR Project

Premium

The European Bioinformatics Institute said this week that Italy has agreed to participate in the European Life-science Infrastructure for Biological Information, or ELIXIR, project.

According to the EBI, Italy has signed a memorandum of understanding that formally commits the signatories to support the development of the pan-European bioinformatics infrastructure.

Anna Tramontano, a professor of biochemistry at the University of Rome, said in a statement that the Italian participation “represents an important opportunity for our national scientific community to contribute in a significant way to solving the critical problems in managing biological data, and transforming that raw data into knowledge.”

Søren Brunak, chair of the ELIXIR Interim Board, described Italy’s decision to participate in ELIXIR as a “positive” one, adding that “we need the competence offered by Italy to complement those offered by the other participating nations so that we may build a strong data infrastructure in Europe.”

“Italy has a long tradition in bioinformatics, and we can benefit from their expertise,” he said.

Italy joins existing ELIXIR contributors Denmark, Estonia, Finland, Israel, the Netherlands, Norway, Slovenia, Spain, Sweden, Switzerland, the UK, and the European Molecular Biology Laboratory (BI 9/16/2011).

Janet Thornton, director of EBI and coordinator of ELIXIR’s preparatory phase, added that “with the support of 12 nations, we are confident that the construction phase of ELIXIR can move forward and we can get this crucial infrastructure off the ground.”

EBI recently broke ground for a new building on the Wellcome Trust Genome Campus in Hinxton, UK, that will house the ELIXIR infrastructure (BI 6/15/2012).

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.